AIM HIGHer

Purpose of Study

Evaluate the efficacy and safety of Cardiac Contractility Modulation (CCM) therapy in patients with symptomatic HF40-60 (HF with LVEF 40-60%).

Trial Status

Enrolling

Eligibility Criteria

LVEF ≥40% and <60% with symptomatic heart failure

Duration of Participation

Approximately 5-6 years

Contact Name: Cayla Garner, RN

Contact Phone: 515-235-5089

Contact Email: cayla.garner@mercyoneiowa.org